Synergy of colistin with rifampin and trimethoprim/sulfamethoxazole on multidrug-resistant Stenotrophomonas maltophilia

Diagnostic Microbiology and Infectious Disease

Volumn 44, Issue 3, 2002, Pages 259-263

  Giamarellos Bourboulis, Evangelos J ^a   Karnesis, Lazaros ^a   Giamarellou, Helen ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

Colistin; Interaction; Rifampin; Stenotrophomonas; Sulfamethoxazole; Trimethoprim

Indexed keywords

COLISTIN; COTRIMOXAZOLE; RIFAMPICIN;

ARTICLE; BACTERIAL GROWTH; BACTERIUM ISOLATE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DISEASE MODEL; DOCUMENTATION; DRUG ACTIVITY; DRUG BLOOD LEVEL; EXPOSURE; GROWTH INHIBITION; IN VITRO STUDY; MULTIDRUG RESISTANCE; NONHUMAN; PRIORITY JOURNAL; STENOTROPHOMONAS MALTOPHILIA; TIME;

ANTI-BACTERIAL AGENTS; COLISTIN; COLONY COUNT, MICROBIAL; CROSS INFECTION; DRUG RESISTANCE, MULTIPLE, BACTERIAL; DRUG SYNERGISM; GRAM-NEGATIVE BACTERIAL INFECTIONS; HUMANS; MICROBIAL SENSITIVITY TESTS; RIFAMPIN; STENOTROPHOMONAS MALTOPHILIA; TRIMETHOPRIM-SULFAMETHOXAZOLE COMBINATION;

EID: 0036863689     PISSN: 07328893     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0732-8893(02)00443-1     Document Type: Article

References (16)

1. Berg G., Roskot N., Smalla K. Genotypic and phenotypic relationships between clinical and environmental isolates of Stenotrophomonas maltophilia. Antimicrob Agents Chemother. 37:1999;3594-3600.
2. Betriu C., Sánchez A., Palau L., Gǒ;mez M., Picazo J.J. Antibiotic resistance surveillance of Stenotrophomonas maltophilia, 1993-1999. J Antimicrob Chemother. 48:2001;152-154.
3. Denton M., Kerr K.G. Microbiological and clinical aspects of infection associated with Stenotrophomonas maltophilia. Clin Microbiol Rev. 11:1998;57-80.
4. Hanberger H., Diekema D., Fluit A., Jones R., Struelens M., Spencer R., Wolff M. Surveillance of antibiotic resistance in European ICUs. J Hosp Infect. 48:2001;161-176.
5. th Edition :2000;348-361 Churchill Livingstone, Philadelphia.
6. Gales A.C., Jones R.N., Forward K.R., Liňeares J., Sader H.S., Verhoef J. Emerging importance of multidrug-resistant Acinetobacter species and Stenotrophomonas maltophilia as pathogens in seriously ill patients geographic patterns, epidemiological features, and trends in the SENTRY antimicrobial surveillance program (1907-1999) . Clin Infect Dis. 32:(Suppl 2):2001;104-113.
7. Gales A.C., Reis A.O., Jones R.N. Contemporary assessment of antimicrobial susceptibility testing methods for polymyxin B and colistin review of available interpretative criteria and quality control guidelines . J Clin Microbiol. 39:2001;183-190.
8. Giacometti A., Cirioni O., Del Prete M.S., Barchiesi F., Fortuna M., Drenaggi D., Scalise G. In vitro activities of membrane-active peptides alone and in combination with clinically used antimicrobial agents against Stenotrophomonas maltophilia. Antimicrob Agents Chemother. 55:2000;1716-1719.
9. Giamarellos-Bourboulis E.J., Xirouchaki E., Giamarellou H. Interactions of colistin and rifampin on multidrug-resistant Acinetobacter baumannii. Diagn Microbiol Infect Dis. 40:2001;117-120.
10. Hindler J. Tests to assess bactericidal activity. Eisenberg H.D. Clinical Microbiology Procedures Handbook. 1992;5.16.14-5.16.24 American Society for Microbiology, Washington.
11. Levin A.S., Barone A.A., Penço J., Santos M.V., Marinho I.S., Arruda E.A.G., Manrique A.I., Costa S.F. Intravenous colistin as therapy for nosocomial infections caused by multidrug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii. Clin Infect Dis. 28:1999;1008-1011.
12. Tascini C., Ferranti S., Messina F., Menichetti F. In vitro and in vivo synergistic activity of colistin, rifampin, and amikacin against a multiresistant Pseudomonas aeruginosa isolate. Clin Microbiol Infect. 6:2000;690-691.
13. Tsiodras S., Pittet D., Carmeli Y., Eliopoulos G., Boucher H., Harbarth S. Clinical implications of Stenotrophomonas maltophilia resistant to trimethoprim-sulfamethoxazole a study of 69 patients at 2 university hospitals . Scand J Infect Dis. 32:2000;651-656.
14. Valdezate S., Vindel A., Loza E., Baquero F., Canton R. Antimicrobial susceptibilities of unique Stenotrophomonas maltophilia clinical isolates. Antimicrob Agents Chemother. 45:2001;1581-1584.
15. Zhang L., Li X.Z., Poole K. SmeDEF multidrug efflux pump contributes to intrinsic multidrug resistance in Stenotrophomonas maltophilia. Antimicrob Agents Chemother. 45:2001;3497-3503.
16. th Edition :2000;394-404 Churchill Livingstone, Philadelphia.